321 related articles for article (PubMed ID: 33953542)
1. No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.
Kim YK; Hwang JG; Park MK
Drug Des Devel Ther; 2021; 15():1725-1734. PubMed ID: 33953542
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator-activated Receptor-γ Agonist, in Healthy Subjects.
Kim CO; Sil Oh E; Kim C; Park MS
Clin Ther; 2015 Sep; 37(9):1999-2006.e1. PubMed ID: 26163202
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State.
Jang K; Jeon JY; Moon SJ; Kim MG
Clin Ther; 2020 Feb; 42(2):295-304. PubMed ID: 31992459
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.
Shin D; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Curr Med Res Opin; 2012 Jul; 28(7):1213-20. PubMed ID: 22697273
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ agonist, after a single oral administration in healthy female subjects.
Park MK; Kim TE; Kim J; Kim C; Yoon SH; Cho JY; Jang IJ; Yu KS; Lim KS
Clin Drug Investig; 2014 Jul; 34(7):467-74. PubMed ID: 24802657
[TBL] [Abstract][Full Text] [Related]
6. An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men.
Moon SJ; Yu KS; Kim MG
Clin Ther; 2020 Jun; 42(6):1047-1057. PubMed ID: 32362346
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects.
Kim H; Kim CO; Park H; Park MS; Kim D; Hong T; Shin Y; Jin BH
Transl Clin Pharmacol; 2023 Mar; 31(1):59-68. PubMed ID: 37034122
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.
Macha S; Mattheus M; Pinnetti S; Broedl UC; Woerle HJ
Clin Ther; 2015 Jul; 37(7):1503-16. PubMed ID: 26051874
[TBL] [Abstract][Full Text] [Related]
9. Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers.
Sil Oh E; Ok Kim C; Kim KH; Kim YN; Kim C; Lee JI; Park MS
Clin Ther; 2014 Jul; 36(7):1064-71. PubMed ID: 25047497
[TBL] [Abstract][Full Text] [Related]
10. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Heise T; Mattheus M; Woerle HJ; Broedl UC; Macha S
Clin Ther; 2015 Apr; 37(4):793-803. PubMed ID: 25636696
[TBL] [Abstract][Full Text] [Related]
11. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
[TBL] [Abstract][Full Text] [Related]
12. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects.
Kim JW; Kim JR; Yi S; Shin KH; Shin HS; Yoon SH; Cho JY; Kim DH; Shin SG; Jang IJ; Yu KS
Clin Ther; 2011 Nov; 33(11):1819-30. PubMed ID: 22047812
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
Brand T; Macha S; Mattheus M; Pinnetti S; Woerle HJ
Adv Ther; 2012 Oct; 29(10):889-99. PubMed ID: 23054692
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open-label Randomized Single-dose Two-sequence, Two-treatment, Two-period Crossover Study.
Chen G; Zhang D; Du A; Zhang Y; Zhang Y; Zhang L; Zang S; Liu X; Wang Z; Zhen H; Liu Y; Yang S; Wang J
Pharmacotherapy; 2020 Jul; 40(7):623-631. PubMed ID: 32498113
[TBL] [Abstract][Full Text] [Related]
17. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
[TBL] [Abstract][Full Text] [Related]
18. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.
Macha S; Jungnik A; Hohl K; Hobson D; Salsali A; Woerle HJ
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):873-9. PubMed ID: 24152604
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.
Laffel LMB; Tamborlane WV; Yver A; Simons G; Wu J; Nock V; Hobson D; Hughan KS; Kaspers S; Marquard J
Diabet Med; 2018 Aug; 35(8):1096-1104. PubMed ID: 29655290
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.
Macha S; Lang B; Pinnetti S; Broedl UC
Int J Clin Pharmacol Ther; 2014 Nov; 52(11):973-80. PubMed ID: 25161155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
